retatrutide triple hormone receptor agonist metabolic Dr Frontiers | Glucagon-like peptide-1 and

Consider periodic breaks of 4-8 weeks to assess your baseline without the compound and allow any potential receptor desensitization to reset

There is no universally accepted 1:1 conversion between GLP-1 RAs

The Effects of NLY01, a novel glucagon-like peptide-1 receptor agonist, on cuprizone-induced demyelination and remyelination: challenges and future perspectives

By engaging the glucagon receptor in addition to the two incretin receptors, retatrutide is hypothesized to add a direct energy-expenditure component to the appetite-suppressing and glucose-regulating effects already established for GLP-1 and GIP agonism